Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—<scp>IL PSO</scp> (<scp>Italian landscape psoriasis</scp>) - Concepedia

Concepedia

Publication | Open Access

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—<scp>IL PSO</scp> (<scp>Italian landscape psoriasis</scp>)

DOI Full Paper Access

41

Citations

17

References

2022

Year

Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, Luciano Ibba, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani,

Journal of the European Academy of Dermatology and Venereology

Abstract

Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in 'real-life' clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52.

References

	Year	Citations

Page 1